ProCE Banner Activity

Venetoclax and Ibrutinib Combination Therapy for Treatment-Naive High-Risk CLL

Slideset Download
Conference Coverage
Venetoclax plus ibrutinib combination regimen in high-risk untreated patients with CLL showed increasing MRD negativity with continued treatment up to 2 years.

Released: December 13, 2019

Expiration: December 11, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company